Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
1987
18K+
LTM Revenue $28.3B
LTM EBITDA $9.7B
$138B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gilead Sciences has a last 12-month revenue of $28.3B and a last 12-month EBITDA of $9.7B.
In the most recent fiscal year, Gilead Sciences achieved revenue of $27.1B and an EBITDA of $10.5B.
Gilead Sciences expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Gilead Sciences valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $27.3B | $27.1B | $28.3B | $28.3B | XXX |
Gross Profit | $20.7B | $21.6B | $20.6B | XXX | XXX |
Gross Margin | 76% | 80% | 73% | XXX | XXX |
EBITDA | $8.9B | $10.5B | $9.2B | $9.7B | XXX |
EBITDA Margin | 32% | 39% | 32% | 34% | XXX |
Net Profit | $6.2B | $4.6B | $5.7B | XXX | XXX |
Net Margin | 23% | 17% | 20% | XXX | XXX |
Net Debt | $21.4B | $19.8B | $18.9B | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 7, 2025, Gilead Sciences's stock price is $96.
Gilead Sciences has current market cap of $120B, and EV of $138B.
See Gilead Sciences trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$138B | $120B | XXX | XXX | XXX | XXX | $4.75 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 7, 2025, Gilead Sciences has market cap of $120B and EV of $138B.
Gilead Sciences's trades at 4.9x LTM EV/Revenue multiple, and 14.3x LTM EBITDA.
Analysts estimate Gilead Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Gilead Sciences and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $138B | XXX | XXX | XXX |
EV/Revenue | 4.9x | XXX | XXX | XXX |
EV/EBITDA | 15.0x | XXX | XXX | XXX |
P/E | 21.6x | XXX | XXX | XXX |
P/E/Growth | 0.6x | XXX | XXX | XXX |
EV/FCF | 13.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGilead Sciences's NTM/LTM revenue growth is 1%
Gilead Sciences's revenue per employee for the last fiscal year averaged $1.5M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Gilead Sciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Gilead Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Gilead Sciences and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 4% | XXX | XXX | XXX | XXX |
EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
EBITDA Growth | -13% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 33% | XXX | XXX | XXX | XXX |
Revenue per Employee | $1.5M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gilead Sciences acquired XXX companies to date.
Last acquisition by Gilead Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Gilead Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Gilead Sciences founded? | Gilead Sciences was founded in 1987. |
Where is Gilead Sciences headquartered? | Gilead Sciences is headquartered in United States of America. |
How many employees does Gilead Sciences have? | As of today, Gilead Sciences has 18K+ employees. |
Who is the CEO of Gilead Sciences? | Gilead Sciences's CEO is Mr. Daniel P. O'Day. |
Is Gilead Sciences publicy listed? | Yes, Gilead Sciences is a public company listed on NAS. |
What is the stock symbol of Gilead Sciences? | Gilead Sciences trades under GILD ticker. |
When did Gilead Sciences go public? | Gilead Sciences went public in 1992. |
Who are competitors of Gilead Sciences? | Similar companies to Gilead Sciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
What is the current market cap of Gilead Sciences? | Gilead Sciences's current market cap is $120B |
What is the current revenue of Gilead Sciences? | Gilead Sciences's last 12-month revenue is $28.3B. |
What is the current EBITDA of Gilead Sciences? | Gilead Sciences's last 12-month EBITDA is $9.7B. |
What is the current EV/Revenue multiple of Gilead Sciences? | Current revenue multiple of Gilead Sciences is 4.9x. |
What is the current EV/EBITDA multiple of Gilead Sciences? | Current EBITDA multiple of Gilead Sciences is 14.3x. |
What is the current revenue growth of Gilead Sciences? | Gilead Sciences revenue growth between 2023 and 2024 was 4%. |
Is Gilead Sciences profitable? | Yes, Gilead Sciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.